drugset / Trial / NCT05238818
Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors
NaSingle-groupOpen-labelTreatment
Summary
A prospective, open-label, non-randomized, Phase 1 study evaluating autologous tumor infiltrating lymphocyte injection (GT202) in the treatment of metastatic or recurrent Gynecological tumors.
Timeline
- Start
- 2022-03
- Primary completion
- 2024-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT202 | Cell therapy | 1e+08 cells | Other |
| Subject | GT202 | Cell therapy | 5e+08 cells | Other |
| Subject | GT202 | Cell therapy | 2e+09 cells | Other |